Cargando...
Population pharmacokinetics of siltuximab: Impact of disease state
PURPOSE: To characterize the effects of disease type and clinical characteristics on the pharmacokinetics of siltuximab, an IL-6 inhibiting monoclonal antibody. METHODS: Siltuximab pharmacokinetic data were combined from 7 phase I/II clinical trials. A population pharmacokinetic model was developed...
Gardado en:
| Publicado en: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800650/ https://ncbi.nlm.nih.gov/pubmed/31482226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03939-7 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|